Personalis Inc - Company Profile
Powered by 
All the sales intelligence you need on Personalis Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Personalis Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Personalis Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Personalis Inc (Personalis) provides genomic sequencing and analytics solutions for developing vaccines to treat cancers. The company develops end-to-end solutions for immuno-oncology through its Immunoid NeXT Platform. It also helps in identifying therapies and clinical trials to treat cancer patients using the NeXT Dx Test, a genomic testing solution. Personalis also offers next-generation sequencing (NGS) assays for the generation and interpretation of molecular data. The company uses accuracy and content-enhanced technology for developing its products. It partners with biopharmaceutical companies to develop cancer therapies and also for personalized medicines. The company has an operational presence in the US and the UK. Personalis is headquartered in Fremont, California, the US.
Headquarters
United States of America
Address
6600 Dumbarton Circle, Fremont, California, 94555
Website
www.personalis.com
Telephone
1 650 7521300
No of Employees
260
Industry
Medical Equipment
Ticker Symbol & Exchange
PSNL (NASD)
Revenue (2024)
$69.6M
-17.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
0%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
-21.5%
(2024 vs 2023)
* As of and is in US$
Personalis Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Technology Platform: | NeXT Personal Dx |
| ImmunoID NeXT Platform | ImmunoID NeXT |
| Next Dx: | NeXT Dx |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with ClearNote Health to provide ClearNote’s Epigenomic Platform to the company's biopharmaceutical partners. |
| 2023 | Contracts/Agreements | In November, the company and Tempus Labs, Inc., entered into a partnership to co-commercialize NeXT Personal Dx. |
| 2023 | Litigation | In June, the company filed a second patent infringement suit against Foresight Diagnostics Inc. |
Competitor Comparison
| Key Parameters | Personalis Inc | Abbott Laboratories | Exact Sciences Corp | Natera Inc | Caris Life Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Fremont | Abbott Park | Madison | Austin | Irving |
| State/Province | California | Illinois | Wisconsin | Texas | Texas |
| No. of Employees | 260 | 115,000 | 7,200 | 6,135 | 1,846 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Karin Eastham | Chairman | Executive Board | 2019 | 76 |
| Christopher Hall | Director; Chief Executive Officer | Executive Board | 2023 | 57 |
| Aaron Tachibana | Chief Operating Officer; Chief Financial Officer | Senior Management | 2019 | 65 |
| Ashish Kheterpal | Chief Information Officer; Senior Vice President | Senior Management | - | - |
| Stephen Moore | Senior Vice President; Secretary; Chief Legal Officer | Senior Management | 2024 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer